- Coya Therapeutics, Inc. priced an underwritten public offering of **3,636,364 shares** of common stock at **$5.50 per share**.  **[1835022_0001193125-25-250709_d52085dex992.htm:0]** 
- The offering includes a 30-day option for the underwriter to purchase up to an additional **545,454 shares**.  **[1835022_0001193125-25-250709_d52085dex992.htm:0]** 
- The gross proceeds are expected to be approximately **$20.0 million** from the initial offering, or approximately **$23.0 million** if the underwriter's option is fully exercised.  **[1835022_0001193125-25-250709_d52085dex992.htm:0]** **[1835022_0001193125-25-250709_d52085d8k.htm:1]** 
- The net proceeds will be used for **working capital and general corporate purposes**, including funding the clinical development plan.  **[1835022_0001193125-25-250709_d52085dex991.htm:0]** **[1835022_0001193125-25-250709_d52085dex992.htm:0]** 
- The offering is expected to close on or about **October 27, 2025**, and directors and executive officers are subject to lock-up agreements until **January 22, 2026**.  **[1835022_0001193125-25-250709_d52085dex992.htm:0]** **[1835022_0001193125-25-250709_d52085d8k.htm:1]**

Coya Therapeutics Prices Upsized Public Offering of Common Stock

- Coya Therapeutics Inc. received a **$4.2 million milestone payment** from its strategic partner, Dr. Reddy's Laboratories Ltd. (DRL), on **August 29, 2025**.  **[1835022_0001193125-25-193450_d95745d8k.htm:1]** 
- This payment was triggered by the U.S. Food and Drug Administration's (FDA) acceptance of Coya's Investigational New Drug Application (IND) for a **Phase 2 clinical study** of **COYA 302** for the treatment of **Amyotrophic Lateral Sclerosis (ALS)**.  **[1835022_0001193125-25-193450_d95745d8k.htm:1]** 
- An **additional $4.2 million payment** is expected from DRL upon the **dosing of the first patient** in the Phase 2 Study.  **[1835022_0001193125-25-193450_d95745d8k.htm:1]**

Coya Therapeutics receives milestone payment for ALS drug study

- Coya Therapeutics announced on **August 25, 2025**, that the U.S. Food and Drug Administration (FDA) has **accepted its Investigational New Drug (IND) application for COYA 302**.  **[1835022_20250825NY57735:0]** 
- This acceptance enables the initiation of a **Phase 2 multicenter, double-blind, placebo-controlled clinical study** to evaluate the efficacy and safety of COYA 302 in patients with **amyotrophic lateral sclerosis (ALS)**.  **[1835022_20250825NY57735:0]** 
- The FDA's IND approval triggers a **$4.2 million milestone payment** to Coya from Dr. Reddy's Laboratories Ltd. (DRL).  **[1835022_20250825NY57735:0]**

Coya Therapeutics (COYA)